Beyond LDL Cholesterol, Residual Risk and the Appropriate Clinical Utility of Advance CVD Tests



About this Webinar

Date: Monday, June 30, 2014

Author: Superko, H. Robert, MD
Chief Medical Officer
Celera Corporation
Alameda, CA
Also by this Author 

Category: Webinar

Description: Robert Superko, MD, discusses the clinical value of advanced lipid testing, the 2013 ACC/AHA Guidelines, its impact on cardiovascular clinical practice, the technological evolution of Ion Mobility and the current clinical research being done to support advanced lipid subclass measurement to CVD risk.
At the conclusion of this program, participants will be able to:
• Understand the new 2013 ACC/AHA Guidelines and their clinical value
• Discuss the clinical data generated by the Jupiter and HATS Trials—the implications of LDL particle-based measures
• Review Ion Mobility Technology and the ongoing research being done to support the link of advanced lipid testing to the measurement of cardiovascular risk